Evidence map›Paper›PMID 19686040›Full record

ReviewAntioxidants & redox signaling2010

Generation and biological activities of oxidized phospholipids.

Valery N Bochkov, Olga V Oskolkova, Konstantin G Birukov, Anna-Liisa Levonen, Christoph J Binder, Johannes Stöckl

Open access · hybridAbstract readReview
In one paragraph

Review in Antioxidants & redox signaling, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 285 papers.

0numbers the graph read from it
0cells of the map it votes in
285citing papers in PubMed
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

285 citing papers in PubMed, 591 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Metabolic Control of Membrane Lipid Asymmetry in Cancer.International journal of molecular sciences · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Observational

225 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Valery N BochkovDepartment of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria. valery.bochkov@meduniwien.ac.at
Olga V Oskolkova
Konstantin G Birukov
Anna-Liisa Levonen
Christoph J Binder
Johannes Stöckl
Medical University of Vienna · ATCeMM Research Center for Molecular Medicine · ATUniversity of Chicago · USUniversity of Eastern Finland · FI

Funding

Control of Lung Permeability by Oxidized PhospholipidsR01HL076259 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI BIRUKOV, KONSTANTIN · 2004 to 2023
$6.8M
NHLBI NIH HHS R01 HL076259
6 · The paper itself

Abstract

Glycerophospholipids represent a common class of lipids critically important for integrity of cellular membranes. Oxidation of esterified unsaturated fatty acids dramatically changes biological activities of phospholipids. Apart from impairment of their structural function, oxidation makes oxidized phospholipids (OxPLs) markers of "modified-self" type that are recognized by soluble and cell-associated receptors of innate immunity, including scavenger receptors, natural (germ line-encoded) antibodies, and C-reactive protein, thus directing removal of senescent and apoptotic cells or oxidized lipoproteins. In addition, OxPLs acquire novel biological activities not characteristic of their unoxidized precursors, including the ability to regulate innate and adaptive immune responses. Effects of OxPLs described in vitro and in vivo suggest their potential relevance in different pathologies, including atherosclerosis, acute inflammation, lung injury, and many other conditions. This review summarizes current knowledge on the mechanisms of formation, structures, and biological activities of OxPLs. Furthermore, potential applications of OxPLs as disease biomarkers, as well as experimental therapies targeting OxPLs, are described, providing a broad overview of an emerging class of lipid mediators.

Indexed as

Oxidation-ReductionPhospholipidsAnimalsBiomarkersBlood Coagulationcdc42 GTP-Binding ProteinCytoskeletonHumansImmune System PhenomenaLipid PeroxidationLungMolecular StructureOxidative StressPlatelet ActivationProto-Oncogene Proteins c-aktReceptors, ScavengerBiomarkerscdc42 GTP-Binding ProteinPhospholipidsProto-Oncogene Proteins c-aktReceptors, Scavenger

Identifiers

PMID19686040
PMCPMC3121779
OpenAlexW2063116304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.